收藏切换
Advances in clinical and safety studies of phosphodiesterase 4 inhibitors
收藏切换
PDF
Hui-fang WANG, You-zhi WANG, Yun-bao ZHI, Lin-fei ZUO, Hui-zhen SHEN, Zheng-wen XU, Jin-xin WANG*
Acta Pharmaceutica Sinica | 2023, 58(9) : 2601 - 2609
Less
收藏切换
Acta Pharmaceutica Sinica | 2023, 58(9): 2601-2609
Advances in clinical and safety studies of phosphodiesterase 4 inhibitors
Full
Hui-fang WANG, You-zhi WANG, Yun-bao ZHI, Lin-fei ZUO, Hui-zhen SHEN, Zheng-wen XU, Jin-xin WANG*
Affiliations
  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
Published: 2023-09-12 doi: 10.16438/j.0513-4870.2022-1401
Outline
收藏切换

Phosphodiesterase 4 (PDE4) is an important member of the phosphodiesterase enzyme family that specifically catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP), activates the downstream phosphorylation cascade pathway by altering cAMP concentration, and is strongly associated with multiple diseases. Inhibition of PDE4 is clinically investigated as a therapeutic strategy in a broad range of disease areas, including respiratory system diseases, autoimmune disorders, central nervous system diseases, and dermatological conditions. However, the incidence of adverse reactions such as nausea and vomiting is relatively high in the marketed PDE4 inhibitors, which has stalled their clinical development. In this review, we provide an overview of the clinical progression and safety issues of the marketed PDE4 inhibitors. We also review the main causes underlying PDE4-mediated adverse effects by combining the structural analysis of the PDE4 protein, the mechanism of action of PDE4 inhibitors, and the related side effect mechanism research, aiming to provide a reference for the development of safe and effective PDE4 inhibitors.

phosphodiesterase  /  phosphodiesterase 4 inhibitor  /  clinical efficacy  /  safety  /  side effect
Hui-fang WANG, You-zhi WANG, Yun-bao ZHI, Lin-fei ZUO, Hui-zhen SHEN, Zheng-wen XU, Jin-xin WANG. Advances in clinical and safety studies of phosphodiesterase 4 inhibitors[J]. Acta Pharmaceutica Sinica, 2023 , 58 (9) : 2601 -2609 . DOI: 10.16438/j.0513-4870.2022-1401
Year 2023 volume 58 Issue 9
PDF
292
120
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-1401
  • Receive Date:2022-12-22
  • Online Date:2025-11-21
  • Published:2023-09-12
Article Data
Affiliations
History
  • Received:2022-12-22
  • Revised:2023-01-31
Funding
Affiliations
    Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-1401
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT